The company plans to use the proceeds to expand its breast cancer risk test and to develop and commercialize a risk assessment test for colorectal cancer.
The technology involves analyzing susceptibility SNPs in order to predict a patient's likelihood of developing colorectal cancer.
The Australian firm regained compliance with a listing rule requiring a minimum $2.5 million in stockholder equity.
The Australian MDx firm will use the financing to support its medium-term capital needs and the commercialization of its BrevaGenplus test.
The Australian molecular diagnostics firm will use the facility to further commercialize its breast cancer test in the US.
The Australian company will use proceeds to ramp up the commercialization of its breast cancer test.
The transaction is part of Genetic Technologies' restructuring of its operations.
NEW YORK (GenomeWeb) – Agilent Technologies said on Monday that Genetic Technologies has dismissed its lawsuit against the company alleging patent infringement.
Originally published Oct. 6.
NEW YORK (GenomeWeb) – Genetic Technologies reported that in its first fiscal quarter of 2015 it received close to 950 patient samples for its BREVAGen test for gauging risk of sporadic, non-hereditary breast cancer.
NEW YORK (GenomeWeb) – Genetic Technologies today reported a 35 percent decrease in gross revenues year over year in its fiscal 2014 revenues.
In PLOS this week: a sequencing-based screen of Lyme disease-causing pathogen, the range of animals bitten by Anopheles darling mosquitoes in Peru, and more.
An NC State researcher is exploring the use of CRISPR-Cas3 as an anti-microbial, Gizmodo reports.
The Earth BioGenome Project plans to sequence all life on Earth, according to ScienceInsider.
For those who are concerned about Trump administration actions related to science, a new column in Scientific American has suggestions for ways to fight back.